Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370054 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
A Phase 3 study of Hemophilia A, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
- 20
- Study locations
NCT04370054 is a Phase 3 study of Hemophilia A that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 77 participants, below the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04370054, a Phase 3 study of Hemophilia A, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
- 20
- Study locations
Study Summary
C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe hemophilia A (FVIII:C≤1%) for the study duration of 5 years. The study will enroll eligible participants who have been followed on routine prophylaxis with FVIII products in the Lead-In study C0371004.
Conditions Studied
Interventions
- BIOLOGICAL PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Study Locations (20)
California
- NOW Physical Therapy - Mountain View
- Clinical and Translational Research Unit (CTRU) - Palo Alto
- Lucile Packard Childrens Hospital - Palo Alto
- Imaging Clinic at Stanford Medicine Outpatient Center in Redwood City - Redwood City
- UCSF IDS Pharmacy - San Francisco
- University of California, San Francisco - Clinical Research Center - San Francisco
- University of California, San Francisco - Moffitt/Long Inpatient Hematology - San Francisco
- University of California, San Francisco - Outpatient Hematology Clinic - San Francisco
- Stanford Health Care - Stanford
Other
- Hopital Necker - Paris
- Vivantes Klinikum im Friedrichshain - Berlin
- Klinikum der Johann Wolfgang Goethe-Universitaet, Medizinische Klinik II - Frankfurt am Main
- General Hospital of Athens "Hippokration" - Athens
Washington
- Washington Institute for Coagulation - Seattle
- University of Washington Medical Center - Translational Research Unit (TRU) - Seattle
Ontario
- McMaster University Medical Centre - Hamilton Health Sciences - Hamilton
- Juravinski Hospital - Hamilton Health Sciences - Hamilton
Victoria
- The Alfred Hospital - Melbourne
São Paulo
- Centro de Hematologia e Hemoterapia de Campinas - Hemocentro UNICAMP - Campinas
Attikí
- General Hospital of Athens ''Laiko'' - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2028-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04370054
The ClinicalTrials.gov registry entry for NCT04370054 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target (14% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy is the first listed.
NCT04370054 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Other, Washington.
Frequently Asked Questions
What is clinical trial NCT04370054 about?
NCT04370054 is a clinical study titled "Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults". C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe hemophilia A (FVIII:C≤1%) for the stud...
What is the current status of trial NCT04370054?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2020-08-18. Estimated completion is 2028-10-25.
What conditions does trial NCT04370054 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT04370054?
The interventions under investigation include: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04370054?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370054 being conducted?
This trial has 20 study locations across California, Washington, Victoria, São Paulo, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RECRUITING · Phase 3
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.